How do patients choose between active surveillance, radical prostatectomy, and radiotherapy? The effect of a preference-sensitive decision aid on treatment decision making for localized prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 35, Issue 2, 2017, Pages 37.e9-37.e17

  Lamers, Romy E D ^a   Cuypers, Maarten ^b   de Vries, Marieke ^c   van de Poll Franse, Lonneke V ^b,d   Ruud Bosch, J L H ^e   Kil, Paul J M ^a  

^a Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^b TILBURG UNIVERSITY   (Netherlands)

^c RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^d Eindhoven Cancer Registry   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Decision aid; Decision making; Patient preferences; Prostate cancer; Treatment

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ACTIVE SURVEILLANCE; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL DECISION MAKING; CONTROLLED STUDY; DECISION AID; DISEASE SURVEILLANCE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SHARED DECISION MAKING; URINE INCONTINENCE; WEB BROWSER; DECISION MAKING; DECISION SUPPORT SYSTEM; MIDDLE AGED; PROCEDURES; PROSTATE TUMOR; PSYCHOLOGY; QUESTIONNAIRE; RADIOTHERAPY; STATISTICS AND NUMERICAL DATA;

AGED; DECISION MAKING; DECISION SUPPORT TECHNIQUES; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SURVEYS AND QUESTIONNAIRES;

EID: 85005958956     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2016.09.007     Document Type: Article

References (26)

1. [1] Hall, J.D., Boyd, J.C., Lippert, M.C., Theodorescu, D., Why patients choose prostatectomy or brachytherapy for localized prostate cancer: results of a descriptive survey. Urology 61 (2003), 402–407.
2. [2] Klotz, L.H., Nam, R.K., Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a “number needed to treat” analysis. Can J Urol 13:Suppl. 1 (2006), 48–55.
3. [3] Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol 65 (2014), 124–137.
4. [4] Bellardita, L., Valdagni, R., van den Bergh, R., et al. How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol 67 (2014), 637–645.
5. [5] Hampson, L.A., Cowan, J.E., Zhao, S., Carroll, P.R., Cooperberg, M.R., Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol 68 (2015), 480–486.
6. [6] Punnen, S., Cowan, J.E., Chan, J.M., Carroll, P.R., Cooperberg, M.R., Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE Registry. Eur Urol 68 (2014), 600–608.
7. [7] Mols, F., Korfage, I.J., Vingerhoets, A.J., et al. Bowel, urinary, and sexual problems among long-term prostate cancer survivors: a population-based study. Int J Radiat Oncol Biol Phys 73 (2009), 30–38.
8. [8] Mols, F., van de Poll‐Franse, L., Vingerhoets, A., et al. Long‐term quality of life among Dutch prostate cancer survivors. Cancer 107 (2006), 2186–2196.
9. [9] van den, Bergh, Roderick, C.N., Essink-Bot, M., Roobol, M.J., Schröder, F.H., Bangma, C.H., et al. Do anxiety and distress increase during active surveillance for low risk prostate cancer?. J Urol 183 (2010), 1786–1791.
10. [10] Peinemann, F., Grouven, U., Bartel, C., et al. Permanent interstitial low-dose-rate brachytherapy for patients with localised prostate cancer: a systematic review of randomised and nonrandomised controlled clinical trials. Eur Urol 60 (2011), 881–893.
11. [11] de Bekker-Grob, E., Bliemer, M., Donkers, B., et al. Patients׳ and urologists׳ preferences for prostate cancer treatment: a discrete choice experiment. Br J Cancer 109 (2013), 633–640.
12. [12] Showalter, T.N., Mishra, M.V., Bridges, J.F., Factors that influence patient preferences for prostate cancer management options: a systematic review. Patient Prefer Adherence, 9, 2015, 899.
13. [13] Holmboe, E.S., Concato, J., Treatment decisions for localized prostate cancer. J Gen Intern Med 15 (2000), 694–701.
14. [14] Davison, B.J., Breckon, E., Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. Patient Educ Couns 87 (2012), 369–374.
15. [15] Diefenbach, M.A., Dorsey, J., Uzzo, R.G., et al. Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol 20 (2002), 55–62.
16. [16] Sommers, B.D., Beard, C.J., D׳Amico, A.V., Kaplan, I., Richie, J.P., Zeckhauser, R.J., Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 113 (2008), 2058–2067.
17. [17] Stalmeier, P.F., van Tol-Geerdink, J.J., van Lin, E.N., et al. Doctors׳ and patients׳ preferences for participation and treatment in curative prostate cancer radiotherapy. J Clin Oncol 25 (2007), 3096–3100.
18. [18] Fowler, F.J. Jr, Collins, M.M., Albertsen, P.C., Zietman, A., Elliott, D.B., Barry, M.J., Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. J Am Med Assoc 283 (2000), 3217–3222.
19. [19] Stacey, D., Légaré, F., Col, N.F., et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev, 1, 2014, CD001431.
20. [20] Oncoline: Richtlijn prostaatcarcinoom.Versie: 2.0, Verantwoording: Nederlandse Vereniging voor Urologie, Type: Landelijke richtlijn; 2014.
21. [21] Ash, D., Flynn, A., Battermann, J., de Reijke, T., Lavagnini, P., Blank, L., ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 57 (2000), 315–321.
22. [22] Cuypers, M., Lamers, R.R., Kil, P.J., van de Poll-Franse, L.V., de Vries, M., Impact of a web-based treatment decision aid for early-stage prostate cancer on shared decision-making and health outcomes: study protocol for a randomized controlled trial. Trials, 16, 2015, 231.
23. [23] Auvinen, A., Hakama, M., Ala‐Opas, M., et al. A randomized trial of choice of treatment in prostate cancer: the effect of intervention on the treatment chosen. BJU Int 93 (2004), 52–56.
24. [24] Tol‐Geerdink, J.J., Willem Leer, J., Weijerman, P.C., et al. Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. BJU Int 111 (2013), 564–573.
25. [25] Bangma, C.H., Bul, M., Roobol, M., The prostate cancer research international: active surveillance study. Curr Opin Urol 22 (2012), 216–221.
26. [26] Klotz, L., Vesprini, D., Sethukavalan, P., et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 33 (2015), 272–277.